|
EP1473292A1
(en)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
IL136768A0
(en)
*
|
1997-12-22 |
2001-06-14 |
Bayer Ag |
INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
ATE529109T1
(de)
*
|
1997-12-22 |
2011-11-15 |
Bayer Healthcare Llc |
Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
|
|
AU2006201959B2
(en)
*
|
1997-12-22 |
2008-09-04 |
Bayer Healthcare Llc |
Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
|
|
DE69831013T2
(de)
*
|
1997-12-22 |
2006-04-20 |
Bayer Pharmaceuticals Corp., West Haven |
Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US7928239B2
(en)
*
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
CA2360934A1
(en)
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
EP1159273A1
(en)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
|
JP2002539206A
(ja)
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
WO2001012189A1
(en)
*
|
1999-08-12 |
2001-02-22 |
Pharmacia Italia S.P.A. |
3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
|
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
|
AU1529901A
(en)
|
1999-11-22 |
2001-06-04 |
Smithkline Beecham Plc |
Compounds
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
DK1320531T3
(da)
|
2000-08-10 |
2011-01-03 |
Pfizer Italia Srl |
Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
JP2004530690A
(ja)
|
2001-05-16 |
2004-10-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症性薬剤として有用なジアリールウレア誘導体
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
EP1709965A3
(en)
*
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
|
US7375105B2
(en)
|
2001-09-05 |
2008-05-20 |
Smithkline Beecham P.L.C. |
Pyridine substituted furan derivatives as Raf kinase inhibitors
|
|
WO2003047579A1
(en)
*
|
2001-12-03 |
2003-06-12 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
CA2493637A1
(en)
*
|
2002-07-25 |
2004-02-12 |
Manuela Villa |
Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
WO2004078748A2
(en)
|
2003-02-28 |
2004-09-16 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
EP1684762A4
(en)
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
UREA DERIVATIVES AS MODULATORS OF KINASE
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
|
ATE496036T1
(de)
*
|
2004-03-19 |
2011-02-15 |
Dipharma Francis Srl |
Zwischenprodukte für die herstellung von pramipexol
|
|
EP2295426A1
(en)
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
EP2258704A1
(en)
|
2004-10-19 |
2010-12-08 |
ArQule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
GB0423554D0
(en)
*
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
CA2592118C
(en)
|
2004-12-23 |
2015-11-17 |
Deciphera Pharmaceuticals, Llc |
Urea derivatives as enzyme modulators
|
|
GB0500435D0
(en)
*
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
|
ATE482693T1
(de)
|
2005-03-07 |
2010-10-15 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
JP5072595B2
(ja)
|
2005-08-05 |
2012-11-14 |
中外製薬株式会社 |
マルチキナーゼ阻害剤
|
|
DE102005037499A1
(de)
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
EP1960394A2
(en)
*
|
2005-11-15 |
2008-08-27 |
Bayer HealthCare AG |
Pyrazolyl urea derivatives useful in the treatment of cancer
|
|
WO2007075650A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Bayer Healthcare Ag |
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
|
|
EP2094268A2
(en)
|
2006-05-26 |
2009-09-02 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
US7897762B2
(en)
|
2006-09-14 |
2011-03-01 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of proliferative diseases
|
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
|
US7737149B2
(en)
*
|
2006-12-21 |
2010-06-15 |
Astrazeneca Ab |
N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
|
|
EP2136639B1
(en)
|
2007-04-02 |
2016-03-09 |
Evotec AG |
Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
|
|
WO2008131276A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
|
JP2011513331A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
|
|
KR20100122505A
(ko)
|
2008-02-29 |
2010-11-22 |
어레이 바이오파마 인크. |
Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
JP2012504591A
(ja)
|
2008-10-02 |
2012-02-23 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
MX2011006219A
(es)
|
2008-12-11 |
2011-06-28 |
Respivert Ltd |
Inhibidores de la proteina cinasa activada por el mitogeno p38.
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
|
|
US20130225581A1
(en)
|
2010-07-16 |
2013-08-29 |
Kyowa Hakko Kirin Co., Ltd |
Nitrogen-containing aromatic heterocyclic derivative
|
|
CA2805874A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
KR101995274B1
(ko)
|
2011-10-03 |
2019-07-02 |
레스피버트 리미티드 |
P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
|
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
KR20140011780A
(ko)
|
2012-07-19 |
2014-01-29 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
|
WO2015066490A1
(en)
|
2013-10-31 |
2015-05-07 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
PT3357919T
(pt)
|
2014-02-14 |
2020-02-20 |
Respivert Ltd |
Compostos heterocíclicos aromáticos como compostos antiinflamatórios
|
|
US10392381B2
(en)
|
2014-07-18 |
2019-08-27 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
CN108484587A
(zh)
*
|
2018-06-03 |
2018-09-04 |
刘思良 |
一种Raf激酶抑制剂及其在癌症治疗中的应用
|
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
|
JP7482122B2
(ja)
*
|
2018-07-03 |
2024-05-13 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|